Pacific Biosciences Of California (PACB) Cash from Financing Activities (2010 - 2026)
Pacific Biosciences Of California (PACB) posted quarterly Cash from Financing Activities of $1.4 million for Q1 2026, down 26.65% year-over-year from $2.0 million in Q1 2025, and down 2.18% quarter-over-quarter from $1.5 million in Q3 2025.
Pacific Biosciences Of California (PACB) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Pacific Biosciences Of California's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 26.65% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $2.9 million (up 106.11% YoY), while the FY2025 annual figure was $3.4 million, up 107.97% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $1.4 million, down from $1.5 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $196.0 million in Q1 2023, with the low at -$81.6 million in Q4 2023.
- The 5-year median for Cash from Financing Activities is $819000.0 (2022), against an average of $5.4 million.
- Peak annual rise in Cash from Financing Activities reached 3658.18% in 2023, while the deepest fall reached 10063.61% in 2023.
- Pacific Biosciences Of California's Cash from Financing Activities stood at $819000.0 in 2022, then plunged by 10063.61% to -$81.6 million in 2023, then jumped by 38.48% to -$50.2 million in 2024, then jumped by 102.93% to $1.5 million in 2025, then slipped by 2.18% to $1.4 million in 2026.
- Business Quant data shows PACB's Cash from Financing Activities at $1.4 million in Q1 2026, $1.5 million in Q3 2025, and $2.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Pacific Biosciences Of California | 381.79 Mn | 144.92 Mn | 12.64 Mn | 255,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 255,000.00 |
| Jun 30, 2026 | 255,000.00 |
| Mar 31, 2026 | 1.44 Mn |
| Mar 31, 2026 | 1.44 Mn |
| Sep 30, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.47 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Mar 31, 2025 | 1.96 Mn |
| Dec 31, 2024 | -50.20 Mn |
| Dec 31, 2024 | -50.20 Mn |
| Sep 30, 2024 | 812,000.00 |
| Sep 30, 2024 | 812,000.00 |
| Jun 30, 2024 | -152,000.00 |
| Jun 30, 2024 | -152,000.00 |
| Mar 31, 2024 | 6.55 Mn |
| Mar 31, 2024 | 6.55 Mn |
| Dec 31, 2023 | -81.60 Mn |
| Dec 31, 2023 | -81.60 Mn |
| Sep 30, 2023 | -781,000.00 |
| Sep 30, 2023 | -781,000.00 |